(CVS) CVS Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1266501006

CVS: Insurance, Pharmacy, Wellness, Drugs, Services, Products

CVS Health Corporation (NYSE: CVS) stands as a pivotal player in the U.S. healthcare landscape, orchestrating a comprehensive suite of health solutions. The companys operational framework is divided into three distinct segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.

The Health Care Benefits segment is a cornerstone of CVSs strategy, offering an array of insurance products including traditional, voluntary, and consumer-directed plans. This segment serves a diverse clientele, ranging from employer groups and individuals to governmental units and expatriates. It provides medical, pharmacy, dental, and behavioral health plans, alongside Medicare Advantage, Medicare Supplement, and Medicaid management services, showcasing its extensive reach and adaptability in the healthcare benefits arena.

The Health Services division specializes in pharmacy benefit management, delivering solutions such as formulary management, disease management, and mail-order pharmacy services. This segment caters to a broad spectrum of clients, including employers, unions, and government entities, underscoring its role as a versatile provider in the health services sector.

The Pharmacy & Consumer Wellness segment operates at the retail level, offering prescription and over-the-counter drugs, as well as consumer health and beauty products. Beyond retail, this segment provides pharmacy consulting services and manages distribution to care facilities, enhancing its role in both direct consumer care and institutional support.

Originally known as CVS Caremark Corporation, the company rebranded as CVS Health Corporation in 2014, signaling its expanded focus on holistic health solutions. With a market capitalization exceeding $83 billion, CVS Health is a significant entity in the healthcare services industry, boasting a P/E ratio of 18.13 and a forward P/E of 11.53, indicating a balanced valuation outlook. Headquartered in Woonsocket, Rhode Island, CVS Health has been a major player in the healthcare sector since its incorporation in 1996.

Additional Sources for CVS Stock

CVS Stock Overview

Market Cap in USD 82,860m
Sector Healthcare
Industry Healthcare Plans
GiC Sub-Industry Health Care Services
IPO / Inception 1984-12-17

CVS Stock Ratings

Growth 5y 1.81%
Fundamental 1.02%
Dividend 69.7%
Rel. Strength Industry -11.8
Analysts 4.07/5
Fair Price Momentum 62.08 USD
Fair Price DCF 115.94 USD

CVS Dividends

Dividend Yield 12m 4.36%
Yield on Cost 5y 5.22%
Annual Growth 5y 5.87%
Payout Consistency 96.5%

CVS Growth Ratios

Growth Correlation 3m 83.8%
Growth Correlation 12m -34.2%
Growth Correlation 5y -2.4%
CAGR 5y 4.98%
CAGR/Max DD 5y 0.09
Sharpe Ratio 12m 0.53
Alpha -18.31
Beta 0.60
Volatility 43.55%
Current Volume 7301.4k
Average Volume 20d 9095.4k
What is the price of CVS stocks?
As of March 12, 2025, the stock is trading at USD 64.98 with a total of 7,301,358 shares traded.
Over the past week, the price has changed by +1.20%, over one month by +18.15%, over three months by +27.14% and over the past year by -10.53%.
Is CVS Health a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, CVS Health is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 1.02 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CVS as of March 2025 is 62.08. This means that CVS is currently overvalued and has a potential downside of -4.46%.
Is CVS a buy, sell or hold?
CVS Health has received a consensus analysts rating of 4.07. Therefor, it is recommend to buy CVS.
  • Strong Buy: 12
  • Buy: 6
  • Hold: 10
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CVS stock price target?
According to ValueRays Forecast Model, CVS CVS Health will be worth about 67.1 in March 2026. The stock is currently trading at 64.98. This means that the stock has a potential upside of +3.31%.
Issuer Forecast Upside
Wallstreet Target Price 72.1 11%
Analysts Target Price 66.3 2%
ValueRay Target Price 67.1 3.3%